Parinda A. Mehta, MD
- Member, Division of Bone Marrow Transplantation and Immune Deficiency
- Professor, UC Department of Pediatrics
- parinda.mehta@cchmc.org
- Board Certified
About
BA: Graduated from Parle College, Mumbai, India, 1988.
MD: G.S. Medical College and K.E.M Hospital, Mumbai, India, 1993.
Residency: Upstate Medical University (UMU) - State University of New York (SUNY), Syracuse, NY, 2002.
Fellowship: Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2005.
Certification: Board Certification, Pediatrics, 2002; Board Certification, Pediatric Hematology Oncology, License, State of Ohio.
Insurance Information
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
Publications
Busulfan Pharmacokinetics and Precision Dosing: Are Patients with Fanconi Anemia Different?. Transplantation and Cellular Therapy. 2019; 25:2416-2421.
Unique Challenges of Hematopoietic Cell Transplantation in Adolescent and Young Adults with Hematologic Malignancies. Transplantation and Cellular Therapy. 2018; 24:e11-e19.
Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study. Pediatric Blood and Cancer. 2018; 65:e27034.
Micafungin antifungal prophylaxis in children undergoing HSCT: can we give higher doses, less frequently? A pharmacokinetic study. Journal of Antimicrobial Chemotherapy. 2018; 73:1651-1658.
Phase 1 study of quercetin, a natural antioxidant for children and young adults with Fanconi anemia. Blood Advances. 2025; 9:1927-1939.
Beyond Graft-Vs-Host Disease: The Role of Cellular Senescence in Persistent Liver Injury in Fanconi Anemia after HSCT. Transplantation and Cellular Therapy. 2025; 31:s311-s312.
Gene Therapy with Reduced-Intensity Conditioning for Sickle Cell Disease. Transplantation and Cellular Therapy. 2025; 31:s2-s3.
Higher Dose Intravenous Posaconazole Is Safe and Necessary for Achievement of Therapeutic Targets and Prevention of Infections in Pediatric Hematopoietic Stem Cell Transplant Patients. Transplantation and Cellular Therapy. 2025; 31:s546.
Impact of Graft Versus Host Disease Following Allogeneic Hematopoietic Cell Transplantation on Leukemia Free Survival in Hematologic Malignancies: A CIBMTR Analysis. Transplantation and Cellular Therapy. 2025; 31:s60-s61.
Impact of Extramedullary Disease on the Outcomes after Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Acute Myeloid Leukemia - a CIBMTR Analysis. Blood. 2024; 144:2412.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2025 Cincinnati Children's Hospital Medical Center. All rights reserved.
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey